Chongqing Huapont Pharmaceutical Co., Ltd.- API's Portfolio,FDF's Protfolio,Collaboration

顶部联系方式

Time of issue:2019-09-22 00:00:00

+86-23-67886927 api@huapont.cn

 中 EN

SEARCH

Confirm

Cancel









01

02





01





EVENTS

DCAT Week NEW YORK CITY, March 20-23, 2023





LEAST NEWS

Huapont Would Attend DCAT, March 20-23, 2023

2023-02-21

Huapont Would Attend DCAT, March 20-23, 2023

Huapont would attend DCAT, March 20-23, 2023. Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there.

See more information

Huapont would attend DCAT, March 20-23, 2023. Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there.

Winning the bidding from centralised procurement

2020-09-22

Winning the bidding from centralised procurement

In order to cut drug prices low enough, China had been pushing forward a system that requires drug manufacturers to go through a bidding process and cut prices low enough if they want to sell their products at public hospitals via large-volume government procurement.

In the last 3 bidding processing, Chongqing Huapont pharm Co., Ltd.’s products: Moxifloxacin tablet, Anastrozole tablet and Levocetirizine HCL tablet were successful won in the centralised procurement process.

Centralised Procurement History:

1st Round: start from 2019 December 15th, total of 25 medicines were open for bidding, covering 11 provinces and regions；

2nd Round: start from 2020 January 17th, total of 33 medicines were open for bidding, covering 23 provinces and regions；

3rd Round: start from 2020 August 20th, total of 56 medicines were open for bidding, covering 25 provinces and regions；

See more information

In order to cut drug prices low enough, China had been pushing forward a system that requires drug manufacturers to go through a bidding process and cut prices low enough if they want to sell their products at public hospitals via large-volume government procurement.

In the last 3 bidding processing, Chongqing Huapont pharm Co., Ltd.’s products: Moxifloxacin tablet, Anastrozole tablet and Levocetirizine HCL tablet were successful won in the centralised procurement process.

Centralised Procurement History:

1st Round: start from 2019 December 15th, total of 25 medicines were open for bidding, covering 11 provinces and regions；

2nd Round: start from 2020 January 17th, total of 33 medicines were open for bidding, covering 23 provinces and regions；

3rd Round: start from 2020 August 20th, total of 56 medicines were open for bidding, covering 25 provinces and regions；

Bexarotene - Potential COVID-19 treatments with recent research

2020-06-29

Bexarotene - Potential COVID-19 treatments with recent research

Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article：Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

See more information

Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article：Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Effect of Ruxolitinib phosphate on COVID-19

2020-06-22

Effect of Ruxolitinib phosphate on COVID-19

April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

See more information

April 2, 2020, Novartis announces plan to initiate clinical study of Ruxolitinib in severe COVID-19 patients and establish international compassionate use program. Patients with COVID-19 can lead to life-threatening respiratory complications due to cytokine storm. Pre-clinical and preliminary clinical evidence suggests Ruxolitinib could reduce the cytokine storm syndromes. In Italy, 7 severe COVID-19 patients in ICU accept Ruxolitinib treatment and getting better, after two days treatment, 5 patients do not need ventilator anymore.

In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.

Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.

PRODUCTS

MORE >>

Serial number:

Acitretin 55079-83-9

．CEP: 2010-038
．GMP: available
．Written Confirmation: available
．CAS No: 55079-83-9
．Chemical Formula: C21H26O3
．Molecular Weight: 326.4
．Specification: the current Ph.Eur., USP, Ch.P
．DMF Open Part: available upon request
．MSDS: available upon request
．Therapeutic class: anti psoriasis

Serial number:

Number of views:

1000

Keywords:

Serial number:

Acrivastine 87848-99-5

Serial number:

Number of views:

1000

Keywords:

Serial number:

Adapalene 106685-40-9

Serial number:

Number of views:

1000

Keywords:

Serial number:

Acitretin 55079-83-9

．CEP: 2010-038
．GMP: available
．Written Confirmation: available
．CAS No: 55079-83-9
．Chemical Formula: C21H26O3
．Molecular Weight: 326.4
．Specification: the current Ph.Eur., USP, Ch.P
．DMF Open Part: available upon request
．MSDS: available upon request
．Therapeutic class: anti psoriasis

Serial number:

浏览量:

1000

关键字:

R&D CENTER

EHS

CDMO

FOCUS ON

Time of issue:2020-05-28 00:00:00

Huapont Pharm has been focusing on retinoids since start-up of its business, and are proud of a lot of experts with rich developing and manufacturing experiences.

We manufacturing APIs including:

● First generation:

　　Tretinoin(Retinoic acid), Isotretinoin and Alitretinoin

● Second generation:

　　Etretinate,Acitretin

● Third generation:

　　Adapalene, Bexarotene and Tazarotene

We also manufacture Tretinoin cream, Isotretinoin soft capsules, Acitretin capsules, Adapalene cream and Tazarotene cream/gel.

NEW PLANT

Time of issue:2020-05-28 00:00:00

A now finished product plant of Huapont Pharm will be put in use in 2018, covering an area about 113516 m² and total construction area more than 180000 m². The new plant is designed to comply with EU GMP with a total investment of billion RMB

With a 5-times capacity increment by comparing the current plant, the new plant has 7 production lines which can manufacture:

● 25 million units for external preparations,

● 35 million units for external preparations(hormones),

● 2 billion units for tablets.

● 0.6 billion units for hard capsules,

● 7.2 million units for small volume injections

● 50 million units for oral solution

● 25 million units for soft capsules.